

## **Supplementary Material**

Article Title: Adjunctive Use of a Standardized Extract of Withania somnifera (Ashwagandha) to Treat

Symptom Exacerbation in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled

Study

Authors: K. N. Roy Chengappa, MD, FRCPC; Jaspreet S. Brar, MBBS, PhD; Jessica M. Gannon,

MD; and Patricia J. Schlicht, BSN, MA

**DOI Number:** 10.4088/JCP.17m11826

#### List of Supplementary Material for the article

Figure 1 Patient Disposition in Study

2. Figure 2 Change in Perceived Stress Scale Scores

3. Figure 3A hsCRP Levels in Patients Receiving Withania somnifera Extract or Placebo Before and

End of Rx

4. Figure 3B S100b Levels in Patients Receiving Withania somnifera Extract or Placebo Before and

End of Rx

5. Table 1 MMRM Analyses Showing Parameter Estimates of Fixed Effects for Treatment\*Visit

Interaction, ie, Time Points at Which the Group Receiving WSE Separates From Placebo, When Compared to the Baseline for PANSS Total, Positive, Negative, General Scores

and for PSS Scores

6. Table 2 Changes in Weight, Body Mass Index and Vital Signs

#### **Disclaimer**


This Supplementary Material has been provided by the author(s) as an enhancement to the published article. It has been approved by peer review; however, it has undergone neither editing nor formatting by in-house editorial staff. The material is presented in the manner supplied by the author.

© Copyright 2018 Physicians Postgraduate Press, Inc.

## Supplementary

## Figure 1

## **Patient Disposition in Study**



## Supplementary Figure 2. Change in Perceived Stress Scale Scores




PSS scores: \*Visit 4: p = 0.025, \*\*Visit 5: p=0.051, \*\*\* Visit 6: p = 0.004, see Supplementary e table 1 for mixed model repeat measures analyses

Visit 1 = baseline, Visit 2 = randomization, Visit 3 = 2 weeks, Visit 4 = 1 month, Visit 5 = 2 months, Visit 6 = 3 months WSE = Withania somnifera extract

## hsCRP Levels in Patients Receiving Withania somnifera Extract or Placebo Before and End of Rx

## **Supplementary Figure 3a**



hsCRP declined more in the WSE group, but was not significantly different from placebo SE = standard error

# S100b Levels in Patients Receiving Withania somnifera Extract or Placebo Before and End of Rx Supplementary Figure 3b

■ WSE Group Placebo Group 100 90 80 SE pg/ml 70 60 50 Mean ± 30 20 10 0 End of Rx Baseline End of Rx Baseline

S100b declined more in the WSE group , but was not significantly different from placebo SE = standard error

## **Supplementary Table 1.**

MMRM Analyses Showing Parameter Estimates of Fixed Effects for Treatment Visit Interaction, i.e. Time Points at which the Group Receiving WSE Separates from Placebo, when compared to the baseline for PANSS total, positive, negative, general scores and for PSS scores

PANSS Total: Estimate of Fixed Effects							
PARAMETER	ESTIMATE	STD. ERROR	df	t	SIGNIFICANCE		
Treatment * Visit 2	515152	1.968737	141.010	262	.794		
Treatment * Visit 3	787879	1.959733	155.444	402	.688		
Treatment * Visit 4	-4.072527	1.949700	194.688	-2.089	.038		
Treatment * Visit 5	-6.864101	1.899797	279.499	-3.613	.000		
Treatment * Visit 6	-9.473726	1.667723	276.864	-5.681	.000		

PANSS Positive Symptoms: Estimate of Fixed Effects							
PARAMETER	METER ESTIMATE STD. ERROR df						
Treatment * Visit 2	.060606	.617366	195.375	.098	.922		
Treatment * Visit 3	666667	.616855	200.967	-1.081	.281		
Treatment * Visit 4	902528	.620219	223.652	-1.455	.147		
Treatment * Visit 5	-1.351543	.618590	285.002	-2.185	.030		
Treatment * Visit 6	-1.775091	.569877	260.751	-3.115	.002		

PANSS Negative Symptoms: Estimate of Fixed Effects							
PARAMETER	ESTIMATE	STD. ERROR	df	t	SIGNIFICANCE		
Treatment * Visit 2	303030	.597105	132.779	507	.613		
Treatment * Visit 3	-1.000000	.591561	153.844	-1.690	.093		
Treatment * Visit 4	-1.312029	.582846	202.762	-2.251	.025		
Treatment * Visit 5	-1.802597	.558483	290.218	-3.228	.001		
Treatment * Visit 6	-2.493988	.477042	277.190	-5.228	.000		

PANSS General Psychopathology: Estimate of Fixed Effects							
PARAMETER	ESTIMATE	df	t	SIGNIFICANCE			
Treatment * Visit 2	272727	1.031668	173.633	264	.792		
Treatment * Visit 3	.060606	1.029368	183.881	.059	.953		
Treatment * Visit 4	-2.783958	1.030242	215.906	-2.702	.007		
Treatment * Visit 5	-3.669332	1.016119	288.116	-3.611	.000		
Treatment * Visit 6	-5.133275	.912648	266.489	-5.625	.000		

PSS Score: Estimate of Fixed Effects							
PARAMETER	ESTIMATE	STD. ERROR	df	t	SIGNIFICANCE		
Treatment * Visit 2	119485	1.283891	288.114	093	.926		
Treatment * Visit 3	-1.783088	1.283891	288.114	-1.389	.166		
Treatment * Visit 4	-2.924631	1.297917	289.636	-2.253	.025		
Treatment * Visit 5	-2.582204	1.318522	289.466	-1.958	.051		
Treatment * Visit 6	-3.911671	1.332804	235.515	-2.935	.004		

Visit 2 = randomization, Visit 3 = 2 weeks of Rx, Visit 4 = one month of Rx, Visit 5 = two months of Rx and Visit 6 = three months of Rx

Abbreviations: MMRM = mixed model repeat measures analyses, PANSS = Positive and Negative Syndrome Scale, PSS = Perceived Stress Scale

It is important for the reader to note that even though the PANSS positive symptom scores for WSE at Visits 5 and 6 are statistically significant versus placebo, that the overall Main Effect for PANSS positive symptoms was not significant.

Supplementary Table 2 - Changes in Weight, Body Mass Index and Vital Signs							Between Groups
	WSE			Placebo			Statistics
	Baseline Mean (SD) N = 33	End of Rx Mean (SD) N = 33	Delta Mean (SD) N = 33	Baseline Mean (SD) N = 33	End of Rx Mean (SD) N = 33	Delta Mean (SD) N = 33	t-test, df, p,
Body Weight (lbs)	194.61 (49.57)	197.00 (51.94)	2.40 (7.04)	191.33 (41.29)	193.06 (41.33)	1.73 (5.66)	0.42, 64, p = 0.67
Body Mass Index	30.00 (7.56)	30.33 (8.04)	0.33 (1.08)	30.36 (6.35)	30.56 (6.24)	0.20 (0.91)	0.53, 64, p = 0.60
Blood Pressure							
Systolic (mm/Hg)	124.67 (10.53)	123.36 (9.30)	-1.31 (8.36)	123.42 (15.32)	118.39 (23.19)	-5.03 (25.24)	0.81, 64, p = 0.42
Diastolic (mm/Hg)	79.15 (7.95)	79.06 (7.31)	-0.09 (6.27)	76.52 (11.52)	75.55 (13.21)	-0.97 (13.60)	0.34, 64, p = 0.74
Pulse (beats/min)	76.18 (13.38)	75.42 (14.64)	-0.76 (10.59)	74.91 (11.75)	76.42 (9.56)	1.51 (8.53)	0.96, 64, p = 0.34
Temperature (°F)	97.38 (0.57)	97.37 (0.73)	-0.01 (0.62)	97.36 (0.72)	97.31 (0.46)	0.05 (0.51)	0.53, 63, p = 0.60

Abbreviations: SD= standard deviation, Rx= treatment, df= degrees of freedom, WSE = standardized extract of Withania somnifera